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The aim of this study was to quantitatively assess the distribution proﬁles of elastic and rigid vesicle material in
human skin in vivo. Furthermore, the distribution proﬁles of the model drug ketorolac applied in these vesicle
formulations was investigated. A deuterium-labelled phospholipid was incorporated into these vesicles to serve as
a marker for the vesicle material. The vesicles were loaded with ketorolac at saturated concentrations. Vesicle
solutions were applied non-occlusively onto the skin and the treated site was sequentially tape-stripped. Tape-
strips were analyzed for vesicle material using attenuated total reﬂectance-Fourier transform infrared spectroscopy
and for ketorolac by extraction of the tape-strips followed by high pressure liquid chromatography. Distribution
proﬁles in the stratum corneum (SC) were obtained for the elastic and rigid vesicle material and for the ketorolac.
These proﬁles have suggested that elastic vesicle material can rapidly enter the deeper layers of the SC and can
reach almost the SC-viable epidermal junction. Rigid vesicle material, however, did not penetrate deep into the SC.
Furthermore, the elastic vesicles were better than the rigid vesicles in the enhancement of ketorolac transport into
human SC. The distribution proﬁle of ketorolac in the deeper SC layers was, however, different from that of the
vesicle material. This suggests that once the elastic vesicles partition into the SC, the ketorolac is released from the
vesicles. The elastic vesicles are superior to the rigid vesicles both in terms of vesicular transport into the SC and
in terms of therapeutic potential as a skin delivery vehicle.
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Vesicles have been widely used in dermatological and cos-
metic preparations in order to enhance drug transport into
and across human skin. In the last decade, a novel type of
vesicles was introduced. These are the elastic vesicles,
which are different from the conventional rigid vesicles in
the fact that they contain elastic membranes. The first gen-
eration of elastic vesicles, also referred to as transfersomes,
was introduced by Cevc and Blume (1992), who combined
phosphatidylcholine with the edge-activator sodium cho-
late. Later, Van den Bergh et al (1999a, b) introduced a new
generation of elastic vesicles, consisting of sole surfactants.
In vitro and in vivo (using mice) transport studies with
non-occlusive application have shown that the elastic ves-
icles were far superior to the conventional rigid vesicles in
the enhancement of drug transport across human and
murine skin (Planas et al, 1992; Cevc et al, 1998; El Ma-
ghraby et al, 1999, 2001; Cevc and Blume, 2001; Honey-
well-Nguyen et al, 2002b, c). These elastic vesicles can
therefore be considered promising candidates for transder-
mal drug delivery, as well as for local drug delivery in der-
matological conditions or cosmetic applications.
Despite these encouraging results, two main factors are
still unclear. Firstly, most transport studies in the past have
been performed with human skin in vitro or with animal skin
in vivo. Very little data on human skin in vivo is available.
Secondly, several questions concerning the transport of
elastic vesicles into the skin are still under discussion. Cevc
et al (2002) suggested that Transfersomes could penetrate
through the skin as intact vesicles. This in vivo study, how-
ever, was performed using mice. We have recently inves-
tigated the in vivo transport of elastic vesicles into human
skin using the tape-stripping technique followed by visual-
ization of the skin using electron microscopy. These results
have shown that intact elastic vesicles could rapidly pen-
etrate into the stratum corneum (SC), whereas rigid vesi-
cles remain on the skin surface (Honeywell-Nguyen et al,
2002a). It was not possible, however, to determine the quanti-
tative distribution profile in the SC. The aim of this study
was 3-fold:
(1) To quantitatively investigate the transport and penetra-
tion depths of elastic and rigid vesicle material into
human skin in vivo.
(2) To quantitatively investigate the transport and penetra-
tion depths of a model-drug from elastic and rigid ves-
icle formulations into human skin in vivo.
Abbreviations: ATR-FTIR, attenuated total reflectance-fourier
transform infrared spectroscopy; DLP, deuterium-labelled phos-
pholipid; HPLC, high pressure liquid chromatography; SC, stratum
corneum; TEWL, trans-epidermal water loss
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(3) By combining the outcome of (1) and (2), we wish to
further elucidate the mechanisms of action of the elastic
vesicles.
In this study, we will prepare surfactant-based elastic and
rigid vesicles. As model drug ketorolac tromethamine ((  )-
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, 2-
amino-2-(hydroxymethyl)-1,3-propanediol) was used in this
study. This drug was chosen based on its physico-chemical
properties, which were suitable for association of the drug
with vesicles. Ketorolac is currently used for the manage-
ment of moderate-to-severe pain, mainly post-operative
pain. The study was performed using tape-stripping fol-
lowed by the quantitative analysis of (a) vesicle material
using attenuated total reflectance-fourier transform infrared
spectroscopy (ATR-FTIR) and (b) ketorolac by extraction of
the tape-strips followed by high pressure liquid chroma-
tography (HPLC). Tape-stripping and ATR-FTIR can be used
to obtain both quantitative distribution profiles as well as
penetration depths of a chemical in human SC (Higo et al,
1993) and therefore perfectly serve the purpose of our
study.
Results
Trans-epidermal water loss (TEWL) as a function of
tape-stripping The curves of all subjects show a similar
profile (not shown). The first 30 tape-strips (50 tape-strips
for subject 2) had little effect on the TEWL values. Further
tape-stripping resulted in a steep rise in the TEWL values.
This was followed by a plateau, where further tape-stripping
did not increase the TEWL values, indicating that the SC
had been almost completely removed. The TEWL values at
this plateau, to be referred to as the ‘maximum TEWL val-
ues’, are given in Table I. The ‘maximum TEWL value’ was
reached after approximately 50 tape-strips in subjects 1, 3–
6 and after approximately 80 tape-strips in subject 2. It is
unclear whether subject 2 differs from the other subjects in
this aspect, because of a thicker SC or because of a more
cohesive SC.
DLP from elastic vesicle formulations penetrated very
deep into the SC and can be found close to the SC-
viable epidermal junction, whereas DPL from rigid ves-
icle formulations did not penetrate as deep into the
SC Figures 1a–f shows the relative peak areas of the C–D
stretching absorbances found in each tape-strip for the 1-h
elastic and rigid vesicle treatments, as well as for the 4-h
elastic vesicle treatment. The relative peak areas represent
the relative amount of deuterium-labelled 1,2-dimyristoyl-
d54-sn-glycero-3-phosphocholine (DLP) found in each
tape-strip, which in its turn is a marker for the relative
amount of vesicle material present. In this study, we did not
remove the excess of vesicle material on the skin surface
before commencing the tape-stripping procedure. Hence,
the DLP present in approximately the first five tape-strips
probably (partly) originated from the surfactant material at
the skin surface, rather than from the SC itself.
From Figs 1a–f it can be deduced that the inter-individual
variation for this in vivo study is quite reasonable. All the
individual curves show a ‘spiky’ nature, however, which can
probably be attributed to the large variation between the
amount of SC removed per tape-strip. The curves from all
treatments and all subjects show a similar profile: the rel-
ative amount of DLP decreases steeply with increasing
number of tape-strips. Little DLP was found in tape-strips
20–40 or 20–60 (subject 2) as compared with what was
found in tape-strips 1–10. When examining the magnifica-
tion graphs embedded in each figure, however, some very
interesting findings can be observed:
(1) 1-h elastic vesicle versus 1-h rigid vesicle treatment: For
the rigid vesicle treatment, DLP could only be observed
up to tape-strips 18–23. TEWL measurements at this
point revealed values of 8–17 g per (m2 h), suggesting
that DLP did not penetrate very deep into the SC. In
contrast, for the elastic vesicle treatment, DLP could be
detected up to tape-strip 40 for subjects 1, 3–6 and up
to tape-strip 60 for subject 2. The very high TEWL values
at this point (see Fig 1) suggest that the SC has been
almost completely stripped off. This indicates that for
the elastic vesicles, DLP can be found close to the SC-
viable epidermal junction. Furthermore, this transport
process is apparently very fast, as DLP was detected
deep in the SC after just a 1-h treatment period.
(2) 1-h elastic vesicle versus 4-h elastic vesicle treatment:
For subjects 1 and 6, the relative amount of DLP was
higher in tape-strips 20–40 after the 4-h treatment as
compared with after the 1-h treatment (Fig 1), whereas
for subject 4 the relative amount of DLP in tape-strips
20–40 was lower after the 4-h treatment. For the re-
maining subjects, no differences were found between
the 1- and the 4-h treatment. In conclusion, there is no
difference in the distribution profile of DLP in the SC
after 1 and 4 h of elastic vesicle treatment.
(3) The distribution profile of DLP in the SC following elastic
vesicle treatment: The distribution profiles of DLP in the
SC following elastic vesicle treatment show a highly re-
markable feature. As can be seen in Fig 1, the relative
amount of DLP decreases steeply with increasing
number of tape-strips as was expected. The magnifica-
tion graphs embedded in each figure, however, clearly
Table I. The percentage of ketorolac recovered in tape-strips
after 1 or 4 h of application and the ‘maximum TEWL values’
Percentage
of drug
recovered
after 1 h
elastic
vesicle
treatment
Percentage
of drug
recovered
after 1 h
rigid
vesicle
treatment
Percentage
of drug
recovered
after 4 h
elastic
vesicle
treatment
Max TEWL
values
(g/(m2hr))
after 50
(subject 1,
3–6) or 80
tape-strips
(subject 2)
Subject 1 91.0 92.7 115.6 67
Subject 2 105.9 93.3 73.8 66
Subject 3 83.4 70.3 101.3 75
Subject 4 82.7 76.2 91.5 88
Subject 5 70.6 78.8 82.8 94
Subject 6 72.0 82.2 97.0 78
The latter is the TEWL value at the plateau, where further tape-stripping
does not increase the TEWL.
TEWL, trans-epidermal water loss.
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show that in five of six subjects the relative amount of
DLP increases from tape-strips 30–40 (subjects 1, 4–6) or
from tape-strips 40–60 (subject 2), suggesting that there
is an accumulation of DLP near the SC-viable epidermal
junction. In subjects 2, 5, and 6 this remarkable feature
was observed in both the 1- and the 4-h treatments.
Elastic vesicles were better than rigid vesicles in the
enhancement of ketorolac transport into human SC As
explained for DLP, the ketorolac present in approximately
the first five tape-strips probably (partly) originated from the
vesicle material at the skin surface. Since the elastic ves-
icles contained 5.0 mg per mL and the rigid vesicles con-
tained 2.5 mg per mL ketorolac, the amount of drug found
on the skin surface (i.e. in the first few tape-strips) will ob-
viously be higher for the elastic vesicle treatment as com-
pared with the rigid vesicle treatment. As both solutions,
however, were saturated solutions, the difference in the
amount of ketorolac found in the SC itself (i.e. beyond the
first few tape-strips) will solely reflect the difference in the
drug transport enhancement effect of these vesicles.
Table I shows the cumulative amount of ketorolac that
has been recovered in all tape-strips as the percentage of
the total amount originally applied on the skin surface for
the three different treatments. Table II shows the mean cu-
mulative amount of ketorolac found in the different layers of
the SC for the three treatments. The curves in Figs 2a–f, in
which the absolute amount of ketorolac in each tape strip
has been plotted, show a similar profile as for the DLP: the
amount of ketorolac decreases fast with increasing number
of tape-strips. Little ketorolac was found in tape-strips
20–40 or 20–60 (subject 2) as compared with what was
found in tape-strips 1–10. When comparing the three
different treatments, the following was observed:
(1) 1-h elastic versus 1-h rigid vesicle treatment: A large
variation can be seen between the ketorolac levels in the
tape-strips of the six subjects. This is partly because of
the inherent variation between skin of different individ-
uals, but can also partly be ascribed to the fact that
tape-stripping does not remove reproducible amounts
of SC. In all subjects, except from subject 3 (Fig 2c), the
Figure 1
The relative peak areas of the C–D stretching absorbances as a function of the number of tape-strips for the 1-h elastic, 1-h rigid, and 4-h
elastic vesicle treatments. This relative peak area is a measurement for the relative amount of deuterium-labelled phospholipid (DLP) in each tape-
strip. For all volunteers and all treatments, the relative amount of DLP decreases steeply with increasing number of tape-strips. Remarkable
differences can be observed between the 1-h elastic and rigid vesicle treatments. DLP from rigid vesicle treatments can be detected up to tape-strip
18–23. Trans-epidermal water loss (TEWL) measurements at this point (8–17 g per (m2 h)) suggest that DLP from rigid vesicle formulations do not
penetrate very deep into the stratum corneum (SC). In contrast to the rigid vesicles, DLP from elastic vesicle formulations can be detected in tape-
strips 40 (subjects 1, 3–6) and 60 (subject 2). TEWL measurements at this point are extremely high (60–80 g per (cm2 h)) and suggest that the SC has
been stripped away almost completely. Hence, these results suggest that DLP from elastic vesicle formulations can penetrate very deep into the SC
and can be found close to the SC-viable epidermal junction. This process is very fast, as these observations were made after 1 h of elastic vesicle
treatment. No clear differences were seen between the 1- and 4-h elastic vesicle treatment. Note that the curve for the elastic vesicles increases
gradually from tape-strips 30–40 or 40–60 (subject 2) suggesting that there is an accumulation of DLP near the SC-viable epidermal junction.
904 HONEYWELL-NGUYEN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
1-h elastic vesicle treatment enhances the ketorolac
transport into the SC as compared with the 1-h rigid
vesicle treatment. The difference between the elastic
and rigid vesicles can only be seen from tape-strips 25
(subjects 1, 3–6) or 40 (subject 2) onwards, that is in the
lower layers of the SC. This is also apparent from Table
II, where for the elastic vesicles the mean cumulative
amount of ketorolac in the lower and lowest layers of the
SC is significantly higher (po0.05) as compared with
what was achieved for the rigid vesicles. No significant
differences were observed in the upper and middle SC
layers.
(2) 1-h elastic versus 4-h elastic vesicle treatment: Table II
shows the cumulative ketorolac levels in the different SC
layers after the 1- and the 4-h elastic vesicle treatment.
Surprisingly, no significant differences were observed
in any part of the SC between the two durations of
treatment.
Discussion
Previous studies have shown that the elastic vesicles were
significantly better than the rigid vesicles in the enhance-
ment of drug transport across human skin in vitro, or across
animal skin in vivo (Planas et al, 1992; Cevc et al, 1998; El
Maghraby et al, 1999, 2001; Cevc and Blume, 2001; Hon-
eywell-Nguyen et al, 2002b, c). Previous studies have also
visualized the transport of elastic and rigid vesicles into hu-
man skin in vivo using electron microscopy (Honeywell-
Nguyen et al, 2002a). No quantification was possible and no
distribution profile of vesicle material in the skin could be
obtained, however. In this study, the quantitative aspects of
both the vesicle material transport as well as of the drug
transport from these vesicle formulations into human skin
in vivo was investigated. This information is essential in or-
der to assess the potential applications of elastic vesicles
as skin delivery vehicles and in order to elucidate their
mechanisms of action.
Tape-stripping and ATR-FTIR Tape-stripping and ATR-
FTIR are suitable methods to determine the distribution
profiles and penetration depths of compounds within hu-
man SC in vivo. They perfectly serve the purpose of our
study, but they also have some limitations.
Tape-stripping One of the limitations of the tape-stripping
technique is the fact that it is not possible to remove re-
producible amounts of the SC. This creates a high intra- and
inter-individual variation and makes it difficult to obtain an
accurate estimation of the skin depth. Matching tape-strips
might not correspond to the same depth within the SC and
it was therefore considered inappropriate to average the
results obtained. Hence, the majority of the results were
presented as the results for each individual subject. The
skin depth was estimated in this study by measuring the
TEWL, which reflects the SC barrier function and hence also
reflects the amount of SC removed (Kalia et al, 1996).
ATR-FTIR This is a widely used technique for the in vivo
assessment of human SC with a few limitations. Firstly, it
should be pointed out that the evanescent wave that prop-
agates from the ATR crystal into the sample has only a lim-
ited penetration depth and is probably not sufficient to
penetrate the entire thickness of the layer of vesicle and
SC material on a single tape-strip, especially in the first
few tape-strips where thick layers of vesicle material are
present. Hence, the result could be an underestimation of
the relative vesicle material in the first few tape-strips.
Another limitation is the fact that the magnitude of the IR
absorbance is affected by the degree of contact between
the tape-strips and the ATR crystal. A normalization pro-
cedure was not possible, as a ‘reference peak’ from the
SC could not be identified as peaks originating from SC
showed too much interference with peaks of the vesicle
material.
The transport of elastic and rigid vesicle material into
human SC The results have shown a remarkable difference
between the elastic and rigid vesicle material penetration:
Rigid vesicle material do not penetrate very deep into the
SC, whereas elastic vesicle material could reach regions
close to its junction with the viable epidermis. Furthermore,
the transport of elastic vesicle material occurs very fast, as
Table II. Cumulative amount of ketorolac found on the skin surface and in the different layers of the SC after elastic
(1- and 4-h treatment) and rigid (1-h treatment) vesicle treatment
1-h elastic vesicle
treatment cum.
amount (lg)  SD
1-h rigid vesicle
treatment cum.
amount (lg)  SD
Enhancement ratio
1-h elastic versus
1-h rigid vesicles
4-h elastic vesicle
treatment cum.
amount (lg)  SD
Skin surfacea 72.23  13.20 32.93  6.26 NA 79.50  10.33
Upper SC layersb 7.35  0.75 5.34  2.42 1.4 7.58  3.08
Middle SC layersc 2.40  0.69 2.20  1.22 1.1 3.84  1.90
Lower SC layersd 1.35  0.70 0.48  0.33 2.8f 1.83  0.90
Lowest SC layerse 0.77  0.42 0.18  0.12 4.2f 0.94  0.50
aSkin surface is assumed to be tape-strips 1–8 (subjects 1, 3–6) or 1–12 (subject 2).
bUpper SC layers is assumed to be tape-strips 9–16 (subject 1, 3–6) or 13–24 (subject 2).
cMiddle SC layers is assumed to be tape-strips 17–24 (subject 1, 3–6) or 25–36 (subject 2).
dLower SC layers is assumed to be tape-strips 25–32 (subject 1, 3–6) or 37–48 (subject 2).
eLowest SC layers is assumed to be tape-strips 33–40 (subject 1, 3–6) or 49–60 (subject 3).
fSignificant difference between elastic and rigid vesicle treatment (po0.05).
SC, stratum corneum.
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the above observations were made after just 1 h of vesicle
treatment. As the estimated path length along the tortuous
route along the crystalline lipid regions in SC is approxi-
mately 100–150 mm (Talreja et al, 2001), according to the
random-walk model, a 100 mm displacement in 1 h would
require diffusion coefficients in the order of magnitude of
small molecules in a liquid phase. This clearly demonstrates
that the transport of elastic vesicle material is not solely
because of diffusion, as in this case a much longer period is
required for the DLP to reach the deepest regions of the SC,
especially if DLP is still associated with the vesicles (see
below).
The results of this study are in excellent agreement with a
recent study, in which we used tape-stripping in combina-
tion with freeze frame electron microscopy (FFEM) (Honey-
well-Nguyen et al, 2002a). The results of the FFEM study
have shown that rigid vesicle material was only visualized in
the superficial layers of the SC, whereas elastic vesicles
were visualized in the deeper layers of the SC 1 h after
vesicle treatment. These vesicles had the same composi-
tion as the vesicles used in this study. It should be noted
that in the FFEM study, only 15 tape-strips were taken as
compared with 40 or 60 (subject 2) tape-strips in this study.
TEWL measurements, however, showed that 15 tape-strips
in the FFEM study corresponded to the deeper SC layers
(unpublished results). This difference in number of tape-
strips was attributed to the fact that different types of tape
and different methods of tape-stripping were employed in
these two studies.
The relative distribution profile of elastic vesicle material
in the SC after 1 and after 4 h of treatment did not show any
difference. This is in line with the observations of Van den
Figure 2
The absolute amount of ketorolac as a function of the number of tape-strips for the 1-h elastic, 1-h rigid, and 4-h elastic vesicle treatment.
For all subjects and all treatments, the amount of ketorolac decreases steeply with increasing number of tape-strips. In subject 3 (c), no differences
can be seen between the 1-h elastic and the 1-h rigid vesicle treatments. In all other five subjects, however, the ketorolac levels found after the 1-h
elastic vesicle treatment were higher as compared with the ketorolac levels found after the 1-h rigid vesicle treatment. This was most clearly seen in
subjects 1 (a) and 6 (f). Interestingly, the difference between elastic and rigid vesicles was only observed from tape-strips 25 (subjects 1, 3–6) or 40
(subject 2) onwards. This suggests that the difference between elastic and rigid vesicles was only present in the deeper layers of the SC.
Surprisingly, no clear differences were observed between the 1- and 4-h elastic vesicle treatment.
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Bergh et al (1999b). They reported that increasing the treat-
ment period from 1 to 16 h did not enhance the penetration
depth of a fluorescently labelled phospholipid incorporated
into elastic vesicles of similar composition. Cevc and Blume
(1992) have suggested that the transport of elastic vesicles
into human skin occurs under the influence of a transep-
idermal osmotic gradient, which justifies the necessity for a
non-occlusive application. Based on our results and those
of Van den Bergh et al (1999b) it can be suggested that the
dehydration process of the vesicle formulation on the skin
surface is a very important factor in the transport of elastic
vesicle material into the skin.
The transport of ketorolac from elastic and rigid vesicle
formulations into human SC Our results have shown that
elastic vesicles were better as compared with rigid vesicles
in the enhancement of the transport of ketorolac into human
SC in vivo. Significantly higher levels of ketorolac were ob-
served in the lower and lowest layers of the SC after elastic
vesicle treatment, but no significant differences were found
in the upper and middle SC layers. No difference was ob-
served in the ketorolac levels found after 1 and after 4 h of
elastic vesicle treatment. Clearly, one would expect to find
higher amounts of ketorolac in the SC after 4 h of treatment.
This might be because of an extremely fast establishment of
the steady-state concentration gradient in the SC.
In this study, only the amount of ketorolac in the SC was
investigated. The transport is also of interest, however, as
the site of action of most drugs is located in the deeper
layers of the skin or in the systemic systems. From this
study, the transdermal ketorolac transport across the SC
cannot be deduced. Most importantly, 180 mL of vesicle
material was applied on a surface area of 9 cm2, of which
1 cm2 was analyzed for ketorolac. As a total even spread of
the vesicle solution on the skin surface cannot be guaran-
teed, it is not possible to determine the exact amount of
ketorolac that was initially applied on the skin surface. Fur-
thermore, the amount of ketorolac transported through the
SC into the viable epidermis within 1 or 4 h is very small,
and hence difficult to determine accurately by subtracting
the amount recovered in the tape-strips from the original
amount applied. This is indicated by results of pilot in vitro
diffusion studies (Fig 3). The cumulative amount of ketorolac
found in the acceptor phase after 4 h of elastic vesicle
treatment was 115.2  59.0 ng per cm2, which is approx-
imately a factor 1000 smaller than the amount of ketorolac
applied onto the skin surface. Figure 3, however, clearly
shows that the elastic vesicles are more effective as com-
pared with the rigid vesicles in enhancing the transdermal
ketorolac transport across human skin in vitro.
How deep do elastic vesicles go? One of the most inter-
esting issues in elastic vesicle research is the question of
how deep the elastic vesicles can penetrate into the skin.
Cevc et al (2002) have suggested that the elastic vesicles
can penetrate through the SC and can even reach the sys-
temic circulation. The results of this study have clearly
shown that elastic vesicle material can reach the deep lay-
ers of the SC close to the SC-viable epidermal junction. It is
likely that some of the elastic vesicle material can penetrate
into the viable epidermis. The amount of vesicle material in
the deeper layers of the SC was found to be very little,
however, as compared with what can be found on the skin
surface. Therefore, even if elastic vesicle material can enter
the viable epidermis, this amount is expected to be very
small. Hence, it is likely that the drug transport enhance-
ment effect of elastic vesicles is mainly attributed by their
fast transport into the SC, rather than by their transport
through the SC into the viable skin layers.
Interestingly, our results have shown that, after elastic
vesicle treatment, in the deeper layers of the SC the amount
of DLP increases with increasing SC depth. These results
suggest that there is an accumulation of elastic vesicle
material near the SC-viable epidermal junction. Cevc et al
(1992) have previously suggested that the transport of elas-
tic vesicles into and across the SC is driven by an osmotic
force, which is the result of the water gradient across the
SC. In recent studies using Cryo-SEM, it was observed that
the water content in the deepest layers of the SC of der-
matomed skin close to the junction with the viable epider-
mis is very low in comparison with the water content in its
superficial or central regions (Bouwstra et al, 2003; Warner
et al, 2003). Therefore, we can hypothesize that, based on
the osmotic force theory of Cevc and Blume (1992), the
elastic vesicles would not penetrate beyond the non-hy-
drated deepest layers of the SC. Instead they accumulate
just above the junction with the viable epidermis, as was
seen from our results.
Figure3
The cumulative amount of ketorolac as a function of time from
elastic and rigid vesicle formulations across human skin in vitro.
Elastic vesicles were clearly more effective as compared with rigid
vesicles in the enhancement of ketorolac transport across the skin. The
cumulative amounts found after 1 and 4 h of elastic vesicle treatment
(corresponding to the time periods chosen for this study), however,
were still very low. Results are presented as mean  SD (n¼4).
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What is the mechanism of action of elastic vesicles? To
date, the mechanism of action of elastic vesicles has not
fully been elucidated. Two mechanisms are most likely to be
involved: (a) a penetration enhancing effect of the individual
vesicle components, and (b) a drug carrier mechanism,
where elastic vesicles carry vesicle-bound drug molecules
into the skin. Results from recent in vitro transport studies
and in vivo visualization studies are strongly in favor of the
second mechanism of action, suggesting that elastic ves-
icles act as a drug carrier system (Honeywell-Nguyen et al,
2002a, 2003). If a drug carrier mechanism is the main mode
of action, drug molecules should be attached to the vesicles
in order for the vesicles to carry these molecules into the
skin. Thus, the results from our study should show a good
correlation between the distribution profiles of DLP and
ketorolac. Figure 4 and Figure S1 shows the distribution pro-
files of DLP and ketorolac plotted in one graph as a function
of the number of tape-strips for subject 2. From this figure
and supplementary figure S1, it is evident that for both the
1- and the 4-h elastic vesicle treatments there is a very good
correlation between DLP and ketorolac in the tape-strips 1–
35. From tape-strips 35 onwards, however, no correlation
was observed. Here the relative amount of DLP increases
whereas the relative amount of ketorolac decreases. This
feature was seen in five of six subjects. These results
strongly suggest that ketorolac was associated with vesicle
material in the first 35 tape-strips, which corresponds to the
upper and middle layers of the SC. This would clearly sup-
port the hypothesis that elastic vesicles act as drug carriers
to carry vesicle-bound drug molecules into the SC, after
which from tape-strip 35 onwards ketorolac has been partly
released from the vesicles. Subsequently, the free ketorolac
diffuses into the viable skin layers. This explains the de-
crease in the relative amount of ketorolac from tape-strip 35
onwards. The elastic vesicle material, however, might not be
able to penetrate through the SC (see above), but instead
accumulates in the lowest layers of the SC, explaining the
increase in the relative amount of DLP from tape-strip 35
onwards. These results are in good agreement with a
mechanism of action for the elastic vesicles that has been
proposed previously by Honeywell-Nguyen et al (2003). Al-
though there is substantial evidence to suggest that elastic
vesicles penetrate into the SC intactly (Cevc et al, 2002;
Honeywell-Nguyen et al, 2002a), it cannot be excluded that
the difference in distribution profile between DLP and
ketorolac in the lowest layers of the SC is because of the
disassembly of the original vesicles and mixing of vesicle
components with endogenous skin lipids, rather than the
partitioning of intact vesicles and vesicle-bound drugs fol-
lowed by the release of the drug.
Conclusions
The results of this study have suggested that elastic vesicle
material can rapidly (within 1 h) enter the SC and can reach
almost as deep as the SC-viable epidermal junction. Rigid
vesicle material, however, do not penetrate as deep into the
SC. Furthermore, elastic vesicles were more effective as
compared with rigid vesicles in the enhancement of the
transport of ketorolac into the SC. The mechanism of action
of the elastic vesicles is most likely that of a drug carrier
system.
Materials and Methods
Materials L-595 consisted of 100% sucrose laurate ester (30%
mono-, 40% di-, and 30% tri-ester) and was kindly supplied by
Mitsubishi Kasei (Tokyo, Japan). The octaoxyethylene laurate ester
(PEG-8-L) was a gift from Lipo Chemicals (Paterson, New Jersey)
and the sodium sulfosuccinate was a gift from Cytec (Rotterdam, the
Netherlands). Deuterium-labelled 1,2-dimyristoyl-d54-sn-glycero-
3-phosphocholine was purchased from Avanti Polar Lipids Inc.
(Alabaster, Alabama). Tora-Dol (Roche Pharma, Reinach, Switzer-
land) (ketorolac tromethamine injection solution, 30 mg per mL in
10% ethyl alcohol (w/v)) was obtained on prescription.
Ketorolac-loaded deuterium-labelled elastic and rigid vesi-
cles The basic components of the elastic vesicles are the bilayer-
forming surfactant L-595 (sucrose laurate ester) and the micelle-
forming surfactant PEG-8-L (octaoxyethylene laurate ester),
Figure 4
The correlation between the relative amounts
of ketorolac and deuterium-labelled phos-
pholipid (DLP) in the tape-strips of 1 h elastic
vesicle application. The relative amount of
ketorolac is expressed as the percentage of the
total amount of drug applied on the skin surface
(100 mg) and the relative amount of DLP is ex-
pressed as the relative peak area of the C–D
symmetrical and asymmetrical stretching vibra-
tions. There is a very good correlation between
the ketorolac and the DLP up to approximately
tape-strip 35. From tape-strip 35 onwards, there
is no good correlation anymore. From this point
onwards the relative amount of DLP increases,
whereas the relative amount of ketorolac de-
creases. These results suggest that ketorolac
was associated with the vesicle material in the
upper and middle parts of the SC, but was re-
leased from the vesicle material in the lowest
part of the SC.
908 HONEYWELL-NGUYEN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
whereas the basic component of the rigid vesicles is solely L-595.
DLP was added to the vesicles to serve as a marker for the pres-
ence of vesicle material in the skin measured by FTIR. Sulfo-
succinate was added to increase vesicle stability. The composition
and the molar ratio of the vesicles used were:
(1) Elastic vesicles: L-595/PEG-8-L/DLP/sulfosuccinate¼ 50/50/
20/5.
(2) Rigid vesicles: L-595/PEG-8-L/DLP/sulfosuccinate¼ 100/0/20/5.
DLP was chosen as a marker for the vesicle material for two rea-
sons. Firstly, a deuterium-labelled compound can be selectively
measured using FTIR. Secondly, because of its very high lipophili-
city and similar chain length as the surfactants, DLP will act as an
additional component forming the membranes of the vesicles, and
hence would be an excellent marker for the distribution of vesicle
material within the SC.
Ketorolac was incorporated into deuterium-labelled elastic
and rigid vesicle formulations at saturated concentrations (5.0
and 2.5 mg per mL total drug concentrations, respectively) to
obtain equal and maximum thermodynamic activities. The latter
resulted in equal driving forces for the partitioning of the drug from
the formulation into the skin. The saturated concentrations of
ketorolac in the vesicle formulations were far above its saturation
concentration in an equivalent buffer solution (150 mg per mL),
which indicates that most of the drug was associated with the
vesicle bilayers.
The elasticity of the vesicles was measured in a previous study
(Van den Berg et al, 2001). The elastic and rigid vesicles had similar
z-average diameters of, respectively, 114.8  10.3 and 126.0 
4.4 nm (mean  SD), as was measured by dynamic light scattering.
Preparation of ketorolac-loaded deuterium-labelled elastic and
rigid vesicles Vesicles were prepared by modification of the soni-
cation method as described by Baillie et al (1985) and Honeywell
et al (2002a). The final elastic and rigid vesicle formulations con-
tained 10% w/w and 9% w/w of lipids, respectively. This was to
assure that the elastic and rigid vesicle formulations contained an
equal concentration of DLP.
Subjects Six healthy subjects (four females and two males), aged
22–37 y (mean 27.7  5.0 y), participated in this study. The study
was approved by the local ethical committee and all subjects gave
written informed consent. None of the subjects had a history of
dermatological diseases. The subjects were asked not to apply any
pharmaceutical or cosmetic skin product on their ventral forearms
within 24 h of the start of the experiment.
Pre-experimental TEWL measurements In order to estimate the
SC depth after tape-stripping, and thus the penetration depth of
vesicles in subsequent experiments, a profile was obtained of the
TEWL values as a function of the number of tape-strips for each
subject. An area of 1 cm2 was marked on the ventral forearm of the
subjects and sequentially tape-stripped (Scotch Magic Tape 810,
3M France, Pethiviers, France). TEWL measurements were taken
after every third tape-strip using a Tewameter TM 210 (Courage &
Khazaka, Cologne, Germany) in a temperature- and humidity-con-
trolled room. The temperature ranged from 191C to 24.31C and the
humidity was approximately 30%. Tape-stripping and TEWL meas-
urements were continued until further tape-stripping did not result
in an increase in the TEWL values. It was assumed that at this
‘maximum TEWL value’ the barrier of the SC was almost com-
pletely removed.
Treatments The study consisted of 2 study days with at least 1
month between each study day. On day 1, 180 mL of ketorolac-
loaded deuterium-labelled elastic and rigid vesicle solutions were
applied non-occlusively onto the ventral forearms of the subjects
over a surface area of 9  1 cm. The site of application was ran-
domized, however, in such a way that each treatment was applied
three times on the left and three times on the right forearm. The SC
was stripped after 1 h of treatment. On day 2, the subjects were
only treated with the elastic vesicle solution and tape-stripping was
commenced after 4 h of treatment.
Tape-stripping was performed using an adhesive tape (Scotch
Magic Tape 810, 3M France), which was pressed to the skin by
rolling it back and forth with a rolling device. Tape-strips were then
rapidly pulled off with one fluent stroke. The direction of tape-
stripping was alternated. After stripping, each tape-strip was cut
into two pieces: a 8  1 cm piece was used to measure the ab-
sorbance peaks of DLP with ATR-FTIR, whereas the remaining
1  1 cm piece was extracted for the amount of ketorolac. TEWL
measurements were taken before, during and after the tape-strip-
ping procedure. Tape-stripping was continued until no DLP could
be detected in the tape-strips, or until the ‘maximum TEWL value’
(see above) was reached. The latter corresponded to 40 tape-
strips for subjects 1, 3–6 and 60 tape-strips for subject 2. These
numbers of tape-strips are lower than those needed to reach the
‘maximum TEWL value’ in the pre-experimental TEWL measure-
ments (see above). This difference can be ascribed to the dif-
ference in tape-stripping of a 1  1 cm area as compared with
tape-stripping a 9  1 cm area.
ATR-FTIR measurements ATR-FTIR spectra were obtained using
a Biorad Excalibur FTS 4000 XM spectrometer (Biorad Laborato-
ries Inc., Cambridge, Massachusetts), equipped with a SHA 10
FTIR air purifying system (Hitma BV, Uithoorn, the Netherlands) and
a mercury–cadmium–telluride detector cooled with liquid nitrogen.
Measurements were taken in the ATR mode using an ATR accessory
(Specar Limited, Orpington, UK), which supports a ZnSe crystal (451
face angle). All spectra were collected with a resolution of 2 per cm in
the frequency range of 4000–400 per cm and were the average of 32
scans.
Tape-strips were placed directly onto the ZnSe crystal with the
adhesive side facing the crystal. Spectra were obtained from each
tape-strip and the relative amount of DLP was determined from the
sum areas of the C–D asymmetrical and C–D symmetrical stretch-
ing vibrations at 2196.9 and 2095.7 per cm. There were no inter-
fering peaks from the absorbance of the SC itself as can be seen in
Fig 5. As FTIR only allows relative quantification, the selected peak
areas were expressed as relative peak areas in percentages. The
relative peak area of each tape-strip was calculated by taking the
peak areas of the C–D symmetrical and C–D asymmetrical stretch-
ing absorbances for a tape-strip and dividing this by the cumulative
peak areas found in the profiles of all measured tape-strips. Since
it can be assumed that there is a linear correlation between the
peak areas of C–D stretching absorbances and the amount of
DLP, the relative peak areas represent the relative amount
of DLP present in a tape-strip. In this way a distribution profile for
DLP within the SC can be obtained.
Analysis of ketorolac Tape-strips were extracted with 2 mL of
methanol under continuous vortexing for 1 h. The methanol solu-
tion was then diluted with a 0.05 M citrate buffer solution pH 5.0
and transferred to HPLC vials. The HPLC system consisted of a
Separations 4000 Solvent Delivery System (Applied Biosystems,
Foster City, California) equipped with a Gilson Model 234 auto-
matic injector (Spectra Physics, Newport, California) and a Waters
2487 Absorbance Detector (Waters, Milford, Massachusetts) set at
a wavelength of 313 nm. Samples were injected onto a Prontosil
Eurobond C18 (125  4.0 mm, 5 mm) column and eluted at 1.0 mL
per min with a mobile phase consisting acetonitrile/0.1 M acetate
buffer (pH 3.6) at a ratio of 4:6 (v/v). This resulted in a retention time
of 3.7 min for ketorolac.
Each experiment was run with a series of standards where
tape-strips were spiked with known concentrations of ketorolac
and subsequently extracted together with the sample tape-strips.
In order to obtain the extraction efficiency, solutions with known
concentrations of ketorolac were injected directly onto the HPLC
system and compared with the extracted standards. The standard
curves for all experiments were linear (r240.998). The average
extraction efficiency was 99.4  3.8% (mean  SD).
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Supplementary Material
The following material is available from http://www.blackwellpublishing.
com/products/journals/suppmat/JID/JID23441/JID23441sm.htm
Figure S1
The correlation between the relative amount of ketorolac and deu-
terium-labelled phospholipid (DLP) in the tape-strips of 4h elastic
vesicle application. The relative amount of ketorolac is expressed as
the percentage of the total amount of drug applied on the skin surface
(100 mg) and the relative amount of DLP is expressed as the relative
peak area of the C–D symmetrical and asymmetrical stretching vibra-
tions. There is a very good correlation between the ketorolac and the
DLP up to approximately tape-strip 35. From tape-strip 35 onwards,
there is no good correlation anymore. From this point onwards the rel-
ative amount of DLP increases, whereas the relative amount of ketoro-
lac decreases. These results suggest that ketorolac was associated with
the vesicle material in the upper and middle parts of the SC, but was
released from the vesicle material in the lowest part of the SC.
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Figure 5
A representative spectrum of a tape-
strip sample. The absorbance peaks at
the position of 2196.9 and 2095.7 per cm
represent the C–D asymmetrical and C–D
symmetrical stretching vibrations, res-
pectively. The areas of these peaks were
used to determine the relative amount of
the deuterium-labelled phospholipid in the
tape-strip. These C–D absorbance peaks
show no interference with other peaks
present in the spectrum.
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